Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon alpha-2a: progressive decrease in hepatitis B surface antigen in responders

Date
2012
Author
Boucher, Charles A.
Pinarbasi, Binnur
Janssen, Harry L. A.
van Vuuren, Anneke J.
Hansen, Bettina E.
Ferenci, Peter
Rijckborst, Vincent
Akdogan, Meral
ter Borg, Martijn J.
Simon, Krzysztof
Flisiak, Robert
AKARCA, ULUS SALİH
Raptopoulou-Gigi, Maria
Verhey, Elke
Metadata
Show full item record
Abstract
Objective Peginterferon (PEG-IFN) is considered as a first-line treatment option for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. We aimed to evaluate the long-term response to PEG-IFN in HBeAg-negative patients.
URI
http://hdl.handle.net/20.500.12627/38043
https://doi.org/10.1097/meg.0b013e3283557e23
Collections